Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Feb 27.
Published in final edited form as: J Am Chem Soc. 2013 Feb 14;135(8):2963–2966. doi: 10.1021/ja400082x

Enantioselective Synthesis of Atropisomeric Benzamides through Peptide-Catalyzed Bromination

Kimberly T Barrett 1, Scott J Miller 1,*
PMCID: PMC3596792  NIHMSID: NIHMS446628  PMID: 23410090

Abstract

We report the enantioselective synthesis of atropisomeric benzamides employing catalytic electrophilic aromatic substitution reactions involving bromination. The catalyst is a simple tetrapeptide bearing a tertiary amine that may function as a Brønsted base. A series of tri- and dibrominations are accomplished for a range of compounds bearing differential substitution patterns. Tertiary benzamides represent appropriate substrates for the reaction since they exhibit sufficiently high barriers to racemization after ortho-functionalization. Mechanism-driven experiments provide some insight into the basis for selectivity. Examination of the observed products at low conversion suggests that the initial catalytic bromination may be regioselective and stereochemistry-determining. A complex between catalyst and substrate is observed by NMR, revealing a specific association. Finally, products of these reactions may be subjected to regioselective metal-halogen exchange and trapping with I2, setting the stage for utility.


Tertiary aromatic amides with appropriate substitution may exhibit axial chirality about the carbonyl carbon-aryl carbon bond axis (Figure 1a).1 With a sufficiently high barrier to interconversion, 1 and ent-1 thus may be isolated and studied as independent entities. These phenomena have been known from the chemical perspective for many years, and more recently, differential biological activity has been noted for isolated enantiomers of chiral benzamide drugs and drug candidates.2 In fact, the property of amide atropisomerism is emerging with great frequency in the medicinal chemistry literature (Figure 1).3 Structures such as 2 (Figure 1b), unless resolved, may exist and function as independent diastereomers.4 Bioactive compounds like 3,5 while they cannot be resolved at physiological temperatures given the low barrier to amide atropisomerization, may also function in one conformation, but might also exhibit deleterious off-target effects in the other rotameric form. As a result, methods for atropisomer-selective synthesis are a current objective. Approaches involving asymmetric ortho-functionalization reactions are described in the literature,6 as are applications of chiral auxiliaries.7 Catalytic asymmetric approaches are less well known, but are now emerging, as exemplified by recent studies of [2+2+2]-cycloadditions8 and dynamic kinetic resolutions.9 We report below an addition to the catalytic, enantioselective approaches to the synthesis of this important class of chiral compounds.

Figure 1.

Figure 1

(a) Chiral benzamides, with barriers to isomerization that are dependent on the nature of A and B. (b) Examples of bioactive compounds that may exist as benzamide atropisomers, with either high barriers to isomerization (2) or low barriers (3).

We previously demonstrated that peptide-based catalysts could be effective for the atropisomer-selective bromination of biaryl compounds to establish axial chirality in a series of biphenyls.10 Given the analogy between the axial chirality implicit in biphenyls, and the axis of chirality intrinsic to benzamides, we wondered if it might be possible to achieve enantioselective reactions of the type shown in Equation 1.

graphic file with name nihms446628e1.jpg (1)

Some keys for effective catalysts in our prior studies appear to include functional groups that could form contacts, perhaps through hydrogen bonding,11 between catalysts and substrates.12 In addition, putative bromine-directing groups (e.g., Lewis base catalysis of bromine transfer involving an amide carbonyl)13 are likely key for bromine-arene bond formation. Catalyst 6 embodies these elements. Peptide 6 contains the dimethylamino-alanine residue (Dmaa), which we felt might target the acidic meta-hydroxyl of the benzamide,14 possibly activating the arene. We elected to embed Dmaa within peptide frameworks we have examined extensively over the years. Among these, the DPro-Aib-Phe-OMe fragment has found utility for a wide variety of enantioselective processes.15 Peptide 6 was projected to possess the capacity to exhibit a β-hairpin structure that could provide conformational constrains favoring bifunctional synergy between the DMAA side chain, and a distal Lewis basic functional group.16

Notably, as shown in equation 2, evaluation of catalyst 6 for the tribromination of substrate 7 yielded an encouraging initial result.17 When the reaction was conducted with 10 mol% 6 (−40 °C; dibromodimethylhydantoin, DBDMH as the brominating agent; CHCl3, 20 h), product 8 could be isolated in 86% yield, exhibiting a 75:25 enantiomer ratio (er). Moreover, when the piperizyl moiety of 7 is replaced with a piperidyl group (i.e., 9; eq 3), the reaction selectivity improves. In this case, tribromide 10 is isolated in 92% yield, with a 90:10 er. Importantly, evaluation of the same sample after 40 days revealed no erosion of the er, reflecting a high barrier to racemization. Evaluation of di-isopropylbenzamide 11 led to further enhancement of selectivity, as 12 is now isolated in 89% yield as a 94:6 enantiomer mixture (eq 4). In this case, the product may also be recrystallized such that it exhibits a 98:2 er (59% recovered after a single recrystallization). Our rationale in evaluating compound 11 involved speculation that the amide itself of substrate 7 or 9 might be responsible as a Lewis base mediator of autocatalytic (and nonselective) bromination. Compound 11 was selected to probe steric inhibition of nonselective catalysis, although this hypothesis remains rigorously unproven..18

graphic file with name nihms446628e2.jpg (2)
graphic file with name nihms446628e3.jpg (3)
graphic file with name nihms446628e4.jpg (4)

We therefore wished to evaluate the substrate scope for this process. As shown in Table 1, in addition to the parent compound 11 (entry 1), a variety of differentially substituted benzamides were explored under standardized conditions. Substituents ortho to the phenol are well-tolerated, with cyclopropyl-substituted amide 13 undergoing conversion to dibromide 14 with a 96:4 er (entry 2, 79% isolated yield). Sterically demanding aryl substitution is also tolerated, as 15 is converted to 16 in 86% yield, with a 93:7 er (entry 3). When a pre-existing bromide is present (as in 17; entry 4), the reaction proceeds similarly and 12 is produced in 89% yield with a 92:8 er. (The mechanistic ramifications of this observation are discussed in greater detail below). The ortho-methyl-bearing substrate 18 is converted to 19 in 69% yield, as a 93:7 mixture of enantiomers (entry 5). meta-Substitution also provides suitable substrates. For example, as shown in entry 6, the cyclopropyl group of 20 is tolerated such that 21 is isolated in 90% yield with a 92:8 er. A phenyl group is also accomodated in this position, and 22 is converted to 23 in 89% yield, with a 93:7 er (entry 7).

Table 1.

Substrate scope for enantioselective bromination of substituted benzamides employing catalyst 6.

Entrya,b Substrate Product Yieldc erd
1 graphic file with name nihms446628t1.jpg
11
graphic file with name nihms446628t2.jpg
12
89 94:6 (recrystallized:98:2; 59% isol.)
2 graphic file with name nihms446628t3.jpg
13
graphic file with name nihms446628t4.jpg
14
79 96:4
3 graphic file with name nihms446628t5.jpg
15
graphic file with name nihms446628t6.jpg
16
86 93:7
4 graphic file with name nihms446628t7.jpg
17
graphic file with name nihms446628t8.jpg
12
89 92:8
5 graphic file with name nihms446628t9.jpg
18
graphic file with name nihms446628t10.jpg
19
69 93:7
6 graphic file with name nihms446628t11.jpg
20
graphic file with name nihms446628t12.jpg
21
90 92:8
7 graphic file with name nihms446628t13.jpg
22
graphic file with name nihms446628t14.jpg
23
89 93:7
8 graphic file with name nihms446628t15.jpg
24
graphic file with name nihms446628t16.jpg
25
80 90:10e
9 graphic file with name nihms446628t17.jpg
26
graphic file with name nihms446628t18.jpg
12
90 52:48
10 graphic file with name nihms446628t19.jpg
27
graphic file with name nihms446628t20.jpg
28
76 63:37
11 graphic file with name nihms446628t21.jpg
29
graphic file with name nihms446628t22.jpg
12
75 51:49
a

Reactions were conducted at −40 °C for 4-48 h, employing 10 mol% 6, 0.02 M in substrate/CHCl3. DBDMH was employed at 1.0 equiv, except for entries 1, 5, and 6 (1.5 equiv). See Supporting Information for details.

b

All experiments in Table 1 were performed in triplicate.

c

Data is reported for the products of the reaction after phenol methylation.

d

Determined by chiral HPLC within one day of synthesis.

e

After 40 days of storage, this sample exhibits 81:19 er (vide infra).

Substitution para to the phenol provides more variation in the results. For example, the para-methyl substituted compound 24 undergoes reaction to give 25 with a slightly reduced er of 90:10 (80% yield, entry 8). However, para-bromine substitution (as in 26, entry 9) leads to a significant drop in selectivity, with 12 isolated in 90% yield, but in near-racemic form (52:48 er). Moreover, as shown in entry 10, a methyl group ortho to both the phenol and the amide (as in 27) also leads to reduced selectivity, as 28 is isolated as a 63:37 enantiomeric mixture, albeit in 76% yield. Compound 29, with Br in the same position, affords a near racemic product (51:49 er; entry 11).

Given the unprecedented nature of this type of catalytic enantioselective approach to atropisomeric amides, we wished to understand the basis for enantioselectivity. These experiments were in large part stimulated by the fact that parent compound 11, and the mono-bromides 17, 26 and 29 each give slightly (entry 1 versus 4), or significantly different (entry 1 versus 9) results in their respective pathways to 12. A particularly revealing experiment involved subjecting substrate 11 to tribromination conditions in the presence or absence of catalyst 6 (Scheme 1). When these reactions are quenched at low conversion,19 different mono-brominated species are apparent in the LCMS and 1H NMR data.20 In the reaction without catalyst 6, the dominant species in the reaction mixture, other than the starting material, is mono-bromide 26, with bromine installed para to the phenol. In addition, mono-bromide 17 is also observed. Mono-bromides 26 and 17 are also the dominant mono-functionalized products when the reaction is conducted in the presence of a simple tertiary amine, such as triethyl amine, under analogous conditions. On the other hand, in the variant where catalyst 6 is employed, the dominant species is instead mono-bromide 29, with bromine installed in the most sterically demanding position, ortho to both the phenol and the amide. These mono-bromides appear to proceed to the corresponding different di-bromides, primarily 30 in the uncatalyzed case; in the catalyzed case, di-bromide 31a may be detected prior to completion of the reaction, along with di-bromide 31b. Our results suggest that the initial bromination in the 6-catalyzed reaction, leading to the formation of 29, may be stereochemistry-determining. This interpretation is consistent with our other observations. As noted, when racemic 26 is the starting material under catalytic conditions (entry 9/Table 1), the substrate is not processed enantioselectively. Perhaps, mono-bromide 26 does not undergo racemization at the low temperature at which the reaction is conducted, en route to di-bromides and eventually 12. Interestingly, when the para-bromide of 26 is replaced with a methyl group (as in 24, entry 8/Table 1), significant enantioselectivity is still observed, consistent with the smaller steric demand of the methyl group relative to bromide in most scales of steric effects relevant to atropisomers.21 Racemization of substrate 24 thus remains possible under these catalytic conditions. Compound 29, with the 2-bromo substituent, is a particularly poor substrate for the reaction since the putative stereochemistry-determining site is blocked, and the substrate may also exhibit a sluggish rate of isomerization under the reaction conditions. Finally, it is also interesting to note that compound 27 (entry 10/Table 1), which blocks what may be the stereochemistry-determining site with a methyl group, is processed with substantially diminished er. It may be that for this case, the site para to the phenol is functionalized in the stereochemistry-determining event, albeit with a less differentiated set of competing transition states. Thus, it is consistent with our observations that a single, initial mono-bromination, ortho to both the phenol and the amide carbonyl, is stereochemistry determining, setting the fate of the atropisomer-selective reaction at that stage.

Scheme 1.

Scheme 1

In pursuit of observable catalyst-substrate interactions, we examined 1H NMR spectra of potentially relevant species (Figure 2). When the spectrum of a 1:1 mixture of 6 and 11 is contrasted with the independent spectra, it is evident that significant alterations in chemical shift result. In particular, changes are observed that are consistent with the formation of complex 32. For example, whereas the Dmaa β-protons (a, a’) appear nearly coincident in the free catalyst, they become distinct and one of the resonances reflects Δδ of 0.29 ppm in the complex. Notably, there is also a loss of degeneracy for the methyl groups associated with the iso-propyl groups of the substrate. Critically, we also observe a significant change in the chemical shift for the proton associated with the aminoisobutyric acid NH (d). In this case, the observed Δδ is 0.24 ppm downfield, consistent with a possible hydrogen bond between the substrate and this locus of the catalyst.22 Finally, the prolyl Cα-proton (c) may be particularly diagnostic. In this case, we observe a Δδ of 0.34 ppm upfield.22 If the catalyst and substrate associate in a manner similar to that drawn for complex 32, we would expect the ring current of the aromatic ring of the substrate to perturb the prolyl Cα-proton in this fashion. It is of further interest to note that if complex 32 is reactive and relevant, one could envision introduction of the stereochemistry-determining bromine atom to appear as shown in complex 33. This particular enantiomer would then go on to form the observed major enantiomer of 12, as demonstrated by heavy atom X-ray crystallography (12-X-ray).23 At this stage, we are unable to pinpoint which of the catalyst carbonyl groups, if any, might be responsible for delivering the electrophilic bromine. It is nonetheless interesting to note that several seem appropriately disposed. One could also readily imagine, for example, dynamics associated with the system in which amide carbonyls participate in hydrogen bonds at one point on the reaction coordinate, but then change roles to deliver bromine at another point.

Figure 2.

Figure 2

Independent NMR spectra of substrate 11, catalyst 6 and the spectrum for their 1:1 co-mixture (0.02 M, CDCl3, 0 °C).

The intriguing nature of this atropisomer selective benzamide synthesis has also stimulated our interest in this approach as a possible entry into drug-like compounds. In this vein, selective functionalization of the various aryl bromide positions could heighten utility.24 To demonstrate the viability of this goal, we subjected 19-(Me) to metal-halogen exchange conditions at low temperature.25 In this experiment, we observed efficient, regioselective lithiation,26 followed by trapping with I2 to give compound 34. Notably, 34 is isolated without loss of er (Eq 5) and as the illustrated regioisomer.27 Trapping with alternative electrophiles, or the selective manipulation of scaffolds like 34 could prove a fruitful path to prepare other atropisomerically enriched benzamides.

graphic file with name nihms446628e5.jpg (5)

In summary, we have discovered an enantioselective bromination process that leads to enantioenriched benzamides. The reaction mechanism is complex, but appears to follow a pathway that involves a clear mechanistic dichotomy between peptide-catalyzed and uncatalyzed variants. Given the increasing attention to atropisomeric compounds in medicinal chemistry,3 we are hopeful that this catalytic process will increase access to this family of structures, which along with mechanistic pursuits, will be the continuing focus of this project.

Supplementary Material

1_si_001
2_si_002
3_si_003

Acknowledgments

We are grateful to the National Institutes of General Medical Sciences of the NIH (GM-068649) for support. We are grateful to Timothy Schmeier for X-ray crystallography.

Footnotes

Supporting Information.

Experimental procedures for all experiments, characterization data. This material is available free of charge via the Internet at http://pubs.acs.org.

References

  • 1.(a) Cuykeng MA, Mannschreck A. Chem Ber. 1987;120:803. [Google Scholar]; (b) Ahmed A, Bragg RA, Clayden J, Lai LW, McCarthy C, Pink JH, Westlund N, Yasin SA. Tetrahedron. 1998;54:13277. [Google Scholar]
  • 2.(a) Ikeura Y, Ishichi Y, Tanaka T, Fujishima A, Murabayashi M, Kawada M, Ishimaru T, Komo I, Doi T, Natsugari H. J Med Chem. 1998;41:4232. doi: 10.1021/jm980042m. [DOI] [PubMed] [Google Scholar]; (b) Albert JS, Ohnmacht C, Berstein PR, Rumsey WL, Aharony D, Alelyunas Y, Russell DJ, Potts W, Sherwood SA, Shen L, Dedinas RF, Palmer WE, Russell K. J Med Chem. 2004;47:519. doi: 10.1021/jm030197g. [DOI] [PubMed] [Google Scholar]; (c) Takahashi H, Wakamatsu S, Tabata H, Oshitari T, Harada A, Inoue K, Natsugari H. Org Lett. 2011;13:760. doi: 10.1021/ol103008d. [DOI] [PubMed] [Google Scholar]
  • 3.(a) Clayden J, Moran WA, Edwards PJ, LaPlante SR. Angew Chem, Int Ed. 2009;48:6398. doi: 10.1002/anie.200901719. [DOI] [PubMed] [Google Scholar]; (b) LaPlante SR, Fader LD, Fandrick HR, Fandrick DR, Hucke O, Kemper R, Miller SPF, Edwards PJ. J Med Chem. 2011;54:7005. doi: 10.1021/jm200584g. [DOI] [PubMed] [Google Scholar]; (c) LaPlante SR, Edwars PJ, Fader LD, Jakalian A, Hucke O. ChemMedChem. 2011;6:505. doi: 10.1002/cmdc.201000485. [DOI] [PubMed] [Google Scholar]
  • 4.Porter J, Payne A, Whitcombe I, de Candole B, Ford D, Garlish R, Hold A, Hutchinson B, Trevitt G, Turner J, Edwards C, Watkins C, Davis J, Stubberfield C. Bioorg Med Chem Lett. 2009;19:1767. doi: 10.1016/j.bmcl.2009.01.071. [DOI] [PubMed] [Google Scholar]
  • 5.(a) Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS. Nature Chem Bio. 2011;7:203. doi: 10.1038/nchembio.538. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, Alessi D, Gray NS. ACS Med Chem Lett. 2012;3:658. doi: 10.1021/ml300123a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.(a) Thayumanavan S, Beak P, Curran DP. Tetrahedron Lett. 1996;37:2899. [Google Scholar]; (b) Clayden J, Johnson P, Pink JH. J Chem Soc, Perkin Trans I. 2001:371. [Google Scholar]; (c) Clayden J. Chem Comm. 2004:127. doi: 10.1039/b307976g. [DOI] [PubMed] [Google Scholar]; (d) Clayden J, Lai LW, Helliwell M. Tetrahedron. 2004;60:4399. [Google Scholar]
  • 7.Koide H, Hata T, Yoshihara K, Kamikawa K, Uemura M. Tetrahedron. 2004;60:4527. [Google Scholar]
  • 8.Suda T, Noguchi K, Hirano M, Tanaka K. Chem Eur J. 2008;14:6593. doi: 10.1002/chem.200800953. [DOI] [PubMed] [Google Scholar]
  • 9.(a) Rios R, Jimeno C, Carroll PJ, Walsh PJ. J Am Chem Soc. 2002;124:10272. doi: 10.1021/ja026436r. [DOI] [PubMed] [Google Scholar]; (b) Dai WM, Zhang Y, Zhang Y. Tetrahedron: Asymmetry. 2003;15:525. [Google Scholar]; (c) Chan V, Kim JG, Jimeno C, Caroll PJ, Walsh PJ. Org Lett. 2004;6:2051. doi: 10.1021/ol0492952. [DOI] [PubMed] [Google Scholar]
  • 10.Gustafson JL, Lim D, Miller SJ. Science. 2010:328. doi: 10.1126/science.1188403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Taylor MS, Jacobsen EN. Angew Chem, Int Ed. 2006;45:1520. doi: 10.1002/anie.200503132. [DOI] [PubMed] [Google Scholar]
  • 12.Garand E, Kamrath MZ, Jordan PA, Wolk AB, McCoy AB, Miller SJ, Johnson MA. Science. 2012;335:694. doi: 10.1126/science.1214948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.(a) Mitchell RH, Lai YH, Williams RV. J Org Chem. 1979;44:4733. [Google Scholar]; (b) Ahmad S, Braddock DC, Hermitage G. Tetrahedron Lett. 2007;48:915. [Google Scholar]; (c) Denmark SE, Burk MT. Proc Natl Acad Sci USA. 2010;107:20655. doi: 10.1073/pnas.1005296107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.(a) Gilli P, Pretto L, Bertolasi V, Gilli G. Acc Chem Res. 2009;42:33. doi: 10.1021/ar800001k. [DOI] [PubMed] [Google Scholar]; (b) Etxebarria J, Degenbeck H, Felten AS, Serres S, Nieto N, Vidal-Ferran A. J Org Chem. 2009;74:8794. doi: 10.1021/jo9015425. [DOI] [PubMed] [Google Scholar]
  • 15.(a) Copeland GT, Jarvo ER, Miller SJ. J Org Chem. 1998;63:6784. doi: 10.1021/jo981642w. [DOI] [PubMed] [Google Scholar]; (b) Jarvo ER, Copeland GT, Papaioannou N, Bonitatebus PJ, Jr, Miller SJ. J Am Chem Soc. 1999;121:11638. [Google Scholar]; (c) Cowen BJ, Saunders LB, Miller SJ. J Am Chem Soc. 2009;131:6105. doi: 10.1021/ja901279m. [DOI] [PubMed] [Google Scholar]; (d) Fowler BS, Mikochik PJ, Miller SJ. J Am Chem Soc. 2010;132:2870. doi: 10.1021/ja9107897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Haque TS, Little JC, Gellman SH. J Am Chem Soc. 1996;118:6975. [Google Scholar]
  • 17.A variety of peptide-based scaffolds were evaluated. It is notable that 6 proved among the best at an early stage in this project. In reactions employing peptides lacking the DMAA residue, no enantioselectivity was observed. The lead catalyst described in reference 10 delivered product 5 in good yield and 36:64 er under similar conditions, with a preference for the opposite enantiomer afforded in the presence of 6.
  • 18.Results were consistent when reactions were performed on scales ranging from 0.2 mmol through 1.0 mmol of substrate. See Supporting Information for details.
  • 19.Reactions are efficiently quenched by the addition of butyl vinyl ether to the reaction mixture at −40 °C.
  • 20.See Supporting Information for details.
  • 21.Bott G, Field LD, Sternhall S. J Am Chem Soc. 1980;102:5618. [Google Scholar]
  • 22.(a) Williams DH, Fleming I. Spectroscopic Methods in Organic Chemistry. 3. McGraw Hill; Maidenhead, UK: 1980. [Google Scholar]; (b) Gomes JANF. Chem Rev. 2001;101:1349. doi: 10.1021/cr990323h. [DOI] [PubMed] [Google Scholar]
  • 23.The absolute sense of chirality for the other compounds in Table 1 is not known, and is drawn as shown only by analogy to 12.
  • 24.Gustafson JL, Lim D, Barrett KT, Miller SJ. Angew Chem, Int Ed. 2011;50:5125. doi: 10.1002/anie.201101147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.(a) Beak P, Allen DJ. J Am Chem Soc. 1992;114:3420. [Google Scholar]; (b) Nájera C, Sansano JM, Yus M. Tetrahedron. 2003;59:9255. [Google Scholar]
  • 26.Gilman H, Langham W, Moore FW. J Am Chem Soc. 1940;62:2327. [Google Scholar]
  • 27.See Supporting Information for details.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1_si_001
2_si_002
3_si_003

RESOURCES